TENLIEX-M

Description

TENLIEX-M contains Teneligliptin HCl I.P. 20 mg and Metformin HCl I.P. 500 mg (S.R.) in a bi-layered tablet formulation. Teneligliptin belongs to the DPP-4 inhibitor group, while Metformin belongs to the biguanide group. Together, they help improve blood glucose control in adults with type 2 diabetes mellitus when used along with appropriate diet, exercise and medical advice.

For related diabetic and cardiovascular formulations, explore the Cardries Biotic range from Medhexa Pharma.

Therapeutic Segment

Anti-Diabetic Therapy | Type 2 Diabetes Management | DPP-4 Inhibitors | Biguanides | Blood Glucose Control

Uses of TENLIEX-M

TENLIEX-M may be prescribed as part of a treatment plan for:

• Type 2 diabetes mellitus
• Patients who need combination therapy with Teneligliptin and Metformin
• Blood glucose levels that remain above the desired range with one medicine alone
• Improving fasting and post-meal blood glucose control
• Long-term diabetes management along with diet and physical activity

The combination works through two different mechanisms. Therefore, healthcare professionals may consider it when treatment with a single medicine does not provide adequate glycaemic control.

Key Benefits of TENLIEX-M

• Dual-action formulation: Combines Teneligliptin and sustained-release Metformin in one tablet.
• Blood Glucose Support: Helps improve blood glucose control in adults with type 2 diabetes.
• Teneligliptin 20 mg: Provides DPP-4 inhibitor activity and supports glucose-dependent insulin release.
• Metformin 500 mg S.R.: Helps reduce glucose production by the liver and improves insulin sensitivity.
• Sustained-Release Metformin: The S.R. component provides the extended-release form of Metformin.
• Bi-Layered Tablet: Combines both active ingredients in a single oral dosage form.
• Convenient Packaging: Supplied in 10 × 10 ALU-ALU packaging.

How TENLIEX-M Works

Teneligliptin is a DPP-4 inhibitor. It slows the breakdown of incretin hormones such as GLP-1 and GIP. As a result, these hormones can support insulin release when blood glucose levels rise. Teneligliptin also helps reduce glucagon release, which can further support blood glucose control.

Metformin belongs to the biguanide class. It mainly reduces glucose production by the liver. In addition, it improves the body’s response to insulin and supports better glucose use by tissues.

Because the two medicines act differently, TENLIEX-M provides complementary blood glucose management. The sustained-release Metformin component also helps provide an extended-release formulation.

Common Side Effects of TENLIEX-M

Some people may experience side effects, particularly during the early stage of Metformin treatment. These may include:

• Nausea
• Diarrhoea
• Vomiting
• Stomach discomfort
• Abdominal bloating
• Flatulence
• Constipation
• Reduced appetite
• Headache
• Low blood sugar, especially when combined with other glucose-lowering medicines

Metformin can commonly cause digestive symptoms. However, these effects may become less troublesome as the body adjusts to treatment.

Contact your healthcare professional if symptoms continue, become severe or interfere with normal activities.

Important Safety Information

Use TENLIEX-M only as prescribed by your healthcare professional.

• Tell your doctor if you have kidney disease because Metformin requires careful consideration of kidney function.
• Your healthcare professional may monitor kidney function during long-term treatment.
• Tell your doctor if you have liver disease, heart problems, dehydration or a history of metabolic acidosis.
• Metformin can rarely cause lactic acidosis, a serious condition. Seek urgent medical attention if you develop severe weakness, unusual sleepiness, breathing difficulty or persistent stomach discomfort.
• Tell your doctor before undergoing an imaging procedure that uses iodinated contrast because Metformin may need temporary interruption in certain situations.
• Teneligliptin can rarely cause pancreatitis. Seek medical attention if you develop persistent or severe abdominal pain, particularly if the pain extends toward the back.
• Low blood sugar can occur more readily when TENLIEX-M is used with insulin or sulfonylureas.
• Tell your healthcare professional about all prescription medicines, vitamins, supplements and herbal products you take.
• Avoid excessive alcohol because it can increase the risk of Metformin-related complications.
• Discuss pregnancy and breastfeeding with your healthcare professional before using the medicine.
• Continue the recommended diet, physical activity and blood glucose monitoring plan.

Current prescribing information also emphasizes renal considerations for Metformin-containing therapy.

For additional prescribing information, refer to the Teneligliptin and Metformin prescribing information.

Dosage & Administration

Take TENLIEX-M exactly as prescribed by your healthcare professional.

For the referenced 20 mg/500 mg teneligliptin and sustained-release Metformin formulation, prescribing information lists once-daily administration. However, the appropriate dose depends on the patient’s blood glucose control, previous treatment, kidney function and response to therapy.

Take the tablet according to the product instructions. Because the formulation contains sustained-release Metformin, do not crush, split or chew the tablet unless the approved product information specifically allows it.

Take the medicine with or after a meal if advised by your healthcare professional. This can also help reduce digestive discomfort associated with Metformin.

If you miss a dose, follow your doctor’s instructions. Do not take an extra tablet to compensate for a missed dose unless specifically advised.

Storage

• Store TENLIEX-M in a cool, dry place.
• Protect the tablets from excessive heat, moisture and direct sunlight.
• Keep the tablets in their original ALU-ALU packaging until use.
• Keep out of the sight and reach of children.
• Do not use the product after the expiry date printed on the pack.